免疫检查点抑制剂相关神经毒性的诊治现状及研究进展  

Current Status and Research Progress in the Diagnosis and Management of Immune Checkpoint Inhibitor-related Neurotoxicity

作　　者：陈华春 吴晓虞 陈桂园[2] 卢周晓 倪小伟 丁明星[2] CHEN Hua-chun;WU Xiao-yu;CHEN Gui-yuan;LU Zhou-xiao;NI Xiao-wei;DING Ming-xing(Department of Respiratory and Critical Care Medicine,Jinhua Guangfu Cancer Hospital,Jinhua 321000,Zhejiang,China;School of Medicine,Jinhua Polytechnic,Jinhua 321007,Zhejiang,China)

机构地区：[1]金华广福肿瘤医院呼吸与危重症医学科,浙江金华321000 [2]金华职业技术学院医学院,浙江金华321007

出　　处：《医学信息》2023年第8期175-179,共5页Journal of Medical Information

基　　金：浙江省基础公益研究计划项目(编号:LGD21C040001);金华市科技计划项目(编号:2022-3-146)。

摘　　要：免疫检查点抑制剂(ICIs)在肿瘤治疗方面取得了突破性进展。接受ICIs治疗的患者可能会因免疫系统活动上调而出现免疫相关不良事件(irAEs)。随着ICIs使用增加,irAEs的报道越来越频繁,并成为许多患者的重要挑战。神经系统irAEs包括脑炎、脊髓炎、脑膜炎、周围神经病、重症肌无力和肌炎等,由一组独特的神经炎症疾病组成。这些疾病罕见但严重,死亡率很高。神经系统irAEs患者通常对免疫调节疗法有反应。因此,早期识别和治疗是改善其预后的重要途径。Immune checkpoint inhibitors(ICIs)have made a breakthrough in cancer therapy.Patients treated with ICIs may develop immune-related adverse events(irAEs)due to the upregulated activity of the immune system.With the increasing use of ICIs,irAEs are more frequently reported and have become important challenges in many patients.Neurological irAEs,which include encephalitis,myelitis,aseptic meningitis,peripheral neuropathy,myasthenia gravis,and myositis,consist of a distinct group of neuroinflammatory disorders.These disorders are rare but frequently severe with high mortality.Patients with neurological irAEs are generally responsive to immune-modulating therapy.Therefore,early recognition and treatment are the most important ways to improve their prognosis.

关 键 词：免疫检查点抑制剂 免疫相关不良事件 神经毒性 糖皮质激素 

分 类 号：R730.5[医药卫生—肿瘤]